Skip to main content

Table 3 Outcomes according to surveillance group

From: Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer– impact on patient anxiety and cancer detection

  MG group n = 94 MG + A-MRI group n = 104, breast findings only MG + A-MRI group n = 104, including extramammary findings  
Outcome P value**
False negativea 3 0 0 -
True negative 87 77 74 -
False positiveb 3 22 24 -
True positive 1 5 6 -
Recall rate 4.3% (4/94) 26% (27/104) 28.9% (30/104)  < 0.0001
Biopsy rate 2.1% (2/94) 19.2% (20/104) 21.2% (22/104) 0.0001
CDR per 1000 10.6 48.1 58 0.1249
Cancers diagnosed per 1000 including follow-up 42.6 48.1 58 0.8522
PPV2 (biopsies recommended) 50% (1/2) 25% (5/20) 27.3% (6/22) 0.4805
PPV3 (biopsies performed) 50% (1/2) 25% (5/20) 27.3% (6/22) 0.4805
Sensitivity 25% (1/4) 100% (5/5) 100% (6/6) 0.048
Specificity 96.7% (87/90) 77.8% (77/99) 75.5% (74/98) 0.0001
  1. aFalse negatives includes breast cancers found at follow-up
  2. bIn the MG plus A-MRI surveillance group, 1 false positive was found with mammography and 2 false positives were found with both MG and A-MRI. All other false positives were found with A-MRI only
  3. **p values were obtained comparing the MG group with the MG + A-MRI surveillance groups for intramammary findings only